Main characteristics of the cohort at PCNSL diagnosis and ICE initiation
| Parameter . | At PCNSL diagnosis . | At ICE treatment . |
|---|---|---|
| Date, n (%) | ||
| Before 2010 | 9 (9) | 0 (0) |
| 2010-2014 | 47 (49) | 46 (47) |
| 2014-2018 | 21 (22) | 20 (21) |
| 2019-2022 | 19 (20) | 31 (32) |
| Age, median (range), y | 64 (33-84) | 65 (34-84) |
| Sex, female, n/N (%) | 41/96 (43) | 41/96 (43) |
| ECOG PS, n/N (%) | ||
| 0-1 | 51/83 (62) | 46/89 (52) |
| >1 | 32/83 (38) | 43/89 (48) |
| 2 | 18/83 (22) | 27/89 (30) |
| 3 | 10/83 (12) | 7/89 (8) |
| 4 | 4/83 (4) | 9/89 (10) |
| Structures involved, n/N (%) | ||
| Brain | 87/96 (91) | 78/94 (83) |
| Deep structures | 51/95 (54) | 50/93 (54) |
| CSF | 21/87 (24) | 29/83 (35) |
| Isolated | 0/87 (0) | 5/83 (6) |
| Ocular | 21/91 (23) | 15/70 (21) |
| Isolated | 9/91 (10) | 5/70 (7) |
| LDH, elevated, n/N (%) | 27/66 (41) | 36/61 (59) |
| Albumin, median (range), g/L | — | 38 (25-47) |
| IELSG prognostic group, n/N (%) | ||
| Low | 13/69 (19) | — |
| Intermediate | 45/69 (65) | — |
| High | 11/69 (16) | — |
| Previous lines before ICE, n/N (%) | ||
| Median (range) | — | 1 (1-3) |
| 1 | — | 70 (73) |
| 2 | — | 21 (22) |
| 3 | — | 5 (6) |
| Type of previous lines | ||
| HD methotrexate | — | 96 (100) |
| HD cytarabine | — | 91 (95) |
| WBRT | — | 7 (7) |
| HDC-ASCT | — | 6 (6) |
| Best response to ICE, n/N (%) | ||
| CR | — | 35/95 (37) |
| PR | — | 31/95 (33) |
| Stable disease | — | 7/95 (7) |
| Progressive disease | — | 22/95 (23) |
| Parameter . | At PCNSL diagnosis . | At ICE treatment . |
|---|---|---|
| Date, n (%) | ||
| Before 2010 | 9 (9) | 0 (0) |
| 2010-2014 | 47 (49) | 46 (47) |
| 2014-2018 | 21 (22) | 20 (21) |
| 2019-2022 | 19 (20) | 31 (32) |
| Age, median (range), y | 64 (33-84) | 65 (34-84) |
| Sex, female, n/N (%) | 41/96 (43) | 41/96 (43) |
| ECOG PS, n/N (%) | ||
| 0-1 | 51/83 (62) | 46/89 (52) |
| >1 | 32/83 (38) | 43/89 (48) |
| 2 | 18/83 (22) | 27/89 (30) |
| 3 | 10/83 (12) | 7/89 (8) |
| 4 | 4/83 (4) | 9/89 (10) |
| Structures involved, n/N (%) | ||
| Brain | 87/96 (91) | 78/94 (83) |
| Deep structures | 51/95 (54) | 50/93 (54) |
| CSF | 21/87 (24) | 29/83 (35) |
| Isolated | 0/87 (0) | 5/83 (6) |
| Ocular | 21/91 (23) | 15/70 (21) |
| Isolated | 9/91 (10) | 5/70 (7) |
| LDH, elevated, n/N (%) | 27/66 (41) | 36/61 (59) |
| Albumin, median (range), g/L | — | 38 (25-47) |
| IELSG prognostic group, n/N (%) | ||
| Low | 13/69 (19) | — |
| Intermediate | 45/69 (65) | — |
| High | 11/69 (16) | — |
| Previous lines before ICE, n/N (%) | ||
| Median (range) | — | 1 (1-3) |
| 1 | — | 70 (73) |
| 2 | — | 21 (22) |
| 3 | — | 5 (6) |
| Type of previous lines | ||
| HD methotrexate | — | 96 (100) |
| HD cytarabine | — | 91 (95) |
| WBRT | — | 7 (7) |
| HDC-ASCT | — | 6 (6) |
| Best response to ICE, n/N (%) | ||
| CR | — | 35/95 (37) |
| PR | — | 31/95 (33) |
| Stable disease | — | 7/95 (7) |
| Progressive disease | — | 22/95 (23) |
CSF, cerebrospinal fluid; ECOG, Eastern Cooperative Oncology Group; IELSG, International Extranodal Lymphoma Study Group.